NCT06251388

A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer

Name: Clinical Trial NCT06251388
Creator: West China Second University Hospital
Keywords: Cervical Cancer, AK104, Phase 2, drug, clinical trial, China

A Prospective, Single Arm, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104) for Newly Diagnosed Local Advanced Cervical Cancer

West China Second University Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Cervical Cancer
Drug/Device/Intervention: AK104
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: West China Second University Hospital
Location: Chengdu, China

Timeline & enrollment

Phase: Phase 2
Start date: Feb 20, 2024
End date: Oct 01, 2026
Enrollment: 50 participants

Primary outcome

Progression-free survival

Summary

This study will evaluate the efficacy and safety of concurrent chemoradiotherapy（CCRT）followed by cadonilimab（AK104) in high risk local advanced cervical cancer.  Participants received CCRT，efficacy evaluation of CCRT was no disease progression who maintained with AK104（10.0 mg/kg，Q3W）until drug exposure over 1 years or disease progression or intolerable toxicity.

ICD-10 classifications

Severe cervical dysplasia, not elsewhere classifiedMild cervical dysplasiaModerate cervical dysplasiaCarcinoma in situ: Cervix, unspecifiedCervical root disorders, not elsewhere classified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06251388
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06251388 through Pure Global AI's free database. This Phase 2 trial is sponsored by West China Second University Hospital and is currently Recruiting. The study focuses on Cervical Cancer. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.